Loading…
In patients newly diagnosed with Breast Cancer, also known as Mammacarcinoma, distant metastases are found in 6% or more of cases. Within this scenario, it has been suggested that locoregional therapy targeting the intact primary tumor might enhance overall survival (OS). However, clinical trials have yielded conflicting results regarding this hypothesis.
Breast Cancer / Mammacarcinoma incidence and mortality rates vary widely across the world
Since 2004, there has been a rise in the incidence of invasive Breast Cancer / Mammacarcinoma among adolescents and young adults in the United States. This increase is largely attributed to a higher number of young women being diagnosed with distant disease. In the U.S., one out of every 196 women is diagnosed with Breast Cancer / Mammacarcinoma under the age of 40. Compared to older women, adolescents and young adults are more prone to presenting with aggressive subtypes and advanced stages of the disease, often necessitating systemic staging at the time of diagnosis.
Breast cancer affects millions each year, making it a major global health concern. It is the most common cancer among women and a top cause of cancer deaths worldwide.
Managing breast cancer is costly, impacting both healthcare systems and families. Diagnosis, treatment, and ongoing care are demanding, highlighting the need for new methods to improve treatment and patient survival
Breast Cancer / Mammacarcinoma is the leading cause of cancer-related deaths among women. This disease, however, has a good long-term prognosis when it is detected in its early stages.
In 2018, global cancer statistics from the International Agency for Research on Cancer (IARC) reported over 2 million new cases and 600,000 deaths due to Breast Cancer / Mammacarcinoma.
The overall survival rate for Breast Cancer / Mammacarcinoma over a 5-year period is 98% for localized diseases, 84% for regional diseases, and just 23% for distant diseases.